Michael King serves as Interim Chief Financial Officer of the Company. He joined the Company in 2014 as the Chief Financial Officer. Mr. King helped take the Company public via a reverse merger with Edge Therapeutics, Inc. in March 2019 and has continued to serve as a financial consultant to the Company since that time. Mr. King is the former long-time Chief Business Officer and Chief Financial Officer of Aprecia Pharmaceuticals, LLC, a specialty pharmaceuticals company that develops branded specialty products using three-dimensional printing, a unique pharmaceutical manufacturing technology. Mr. King has served as a senior advisor to a number of early-stage public and private biotechnology and biopharmaceutical companies. Mr. King was Chief Business Officer of Atrin Pharmaceuticals, Chief Commercial Officer of Belrose Pharma, as well as Head of US Product Portfolio & Strategy, and a member of the U.S. Executive Committee, for Sandoz GmbH, the $10 billion subsidiary of Novartis AG. A former management consultant with McKinsey & Company, Mr. King has a diverse background in corporate finance and sell-side analyst research, with deep knowledge of the pharmaceutical/biotechnology industry. Mr. King holds a Masters of Business Administration with Honors from the Columbia Graduate School of Business and a Bachelor of Arts from Wesleyan University.
Michael King is 50, he's been the Interim Chief Financial Officer of PDS Biotechnology since 2020. There are 14 older and no younger executives at PDS Biotechnology. The oldest executive at PDS Biotechnology Corporation is Richard Sykes, 78, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK, NJ, 07932.
Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin a Kamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
PDS Biotechnology executives and other stock owners filed with the SEC include: